Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.

Abstract

High-risk resectable melanoma poses therapeutic challenges as this subgroup remains most vulnerable for disease recurrence. Immunotherapy has established its efficacy in cases of advanced melanoma, and now is actively being investigated in the multimodal management of resectable disease. Daromun, an intralesional immunocytokine, has emerged as a unique immunotherapy in its ability to preferentially target tumor cells, resulting in direct destruction, while generating a bystander effect that leads to a distant treatment effect. On the basis of its mechanism of action, there is growing interest in delivering immune-based therapies in a neoadjuvant setting. In this review, the neo-DREAM study, a Phase III trial comparing the safety and efficacy of neoadjuvant Daromun for resectable stage IIIB/C melanoma will be described. Clinical Trial Registration Number: NCT03567889.

• Authors: John T Miura, Jonathan S Zager
• Journal: Future oncology (London, England) (Future Oncol) Vol. 15 Issue 32 Pg. 3665-3674 (Nov 2019) ISSN: 1744-8301 [Electronic] England
• PMID: 31538818 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Cytokines
• L19-IL2 immunocytokine
• L19mTNFalpha protein
• Recombinant Fusion Proteins
• daromun

Topics

• Antineoplastic Agents (therapeutic use)
• Clinical Trials, Phase III as Topic
• Cytokines (therapeutic use)
• Humans
• Immunotherapy
• Melanoma (drug therapy, pathology, surgery)
• Neoadjuvant Therapy
• Randomized Controlled Trials as Topic
• Recombinant Fusion Proteins (therapeutic use)
• Skin Neoplasms (drug therapy, pathology, surgery)